Minnesota Moves Closer to Expanding Access to Psilocybin Therapy
Minnesota is moving closer to creating a regulated psilocybin therapy program, although legal access will not begin this year. Lawmakers approved a feasibility study that could shape a future system for supervised treatment. The Office of Cannabis Management must deliver its recommendations by January 15, 2027.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Key Takeaways
| Key takeaway | What it means |
|---|---|
| Access is not legal yet | Minnesota has not authorized psilocybin treatment or personal possession. |
| A state study is underway | Regulators will examine how a supervised therapy program could operate. |
| The report is due in 2027 | Lawmakers could use the findings to introduce a new access bill next year. |
| Patients would face screening | The proposed model focuses on adults with qualifying health conditions. |
| Minnesota has a policy blueprint | A state task force has already produced a detailed report on psychedelic medicine. |
Do you work in the ketamine industry? Save thousands on overhead and other fees by joining the first GPO for ketamine clinics and practitioners. There’s no cost to join and zero obligations. Sign up here!
Minnesota Chose Planning Over Immediate Access
Minnesota lawmakers considered legislation that would have established a therapeutic psilocybin program during the 2026 session. The proposal gained bipartisan support but did not reach the finish line.
Instead, lawmakers directed the Office of Cannabis Management to study the practical details of implementation. The agency will examine regulation, patient eligibility, safety standards and program oversight.
That distinction matters. The state is not simply studying whether psilocybin has therapeutic value. Officials are now studying how Minnesota might deliver it responsibly.
The proposed framework would serve patients who complete screening and have an approved health condition. Treatment would likely take place in supervised settings with trained facilitators.
A Task Force Has Already Done Much of the Work
Minnesota created its Psychedelic Medicine Task Force in 2023. The group spent 14 months reviewing the medical, legal, ethical and cultural questions surrounding psychedelic therapies.
Its final report runs about 200 pages and offers lawmakers a substantial starting point. It covers clinical safeguards, facilitator standards, patient protections, Indigenous perspectives and possible regulatory structures.
That groundwork may help Minnesota avoid some of the delays seen in other states. Regulators can also study the experiences of Oregon, Colorado and New Mexico, which have approved forms of supervised psychedelic access.
Still, a detailed report does not guarantee an accessible program. Costs, insurance coverage and provider availability could determine who benefits. Strict rules may improve safety while placing treatment beyond the reach of many patients.
The Next Decision Could Come in 2027
Supporters describe the current study as a planning phase rather than a setback. The January report could give legislators the information needed to pass a complete access program in 2027.
Any future proposal will face difficult choices. Minnesota must decide which conditions qualify, who may facilitate treatment and where sessions may occur. Officials must also determine how to monitor outcomes and respond to adverse events.
Psilocybin remains illegal under federal law outside approved research and limited federal pathways. Minnesota would therefore need to build a state system within an unsettled national landscape.
For patients with depression, trauma or addiction, the timeline may feel slow. Yet Minnesota’s deliberate approach could produce a more durable program. The coming months will reveal whether lawmakers can turn years of research and discussion into supervised, practical access.
